Updated on 2025/03/21

写真a

 
SHIMADA, Satoko
 
Organization
Nagoya University Hospital Anatomical Pathology Assistant professor of hospital
Title
Assistant professor of hospital

Degree 1

  1. 医学博士 （ 名古屋大学 ） 

To the head of Degree.▲

Research Areas 1

  1. Others / Others  / Human Pathology

To the head of Research Areas.▲

Current Research Project and SDGs 1

  1. 診断病理学

To the head of Current Research Project and SDGs.▲

Education 1

  1. Nagoya University

    1995.4 - 2001.3

To the head of Education.▲
 

Papers 40

  1. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial Open Access

    Shimada, K; Yamaguchi, M; Kuwatsuka, Y; Matsue, K; Sato, K; Kusumoto, S; Nagai, H; Takizawa, J; Fukuhara, N; Nagafuji, K; Miyazaki, K; Ohtsuka, E; Okamoto, A; Sugita, Y; Uchida, T; Kayukawa, S; Wake, A; Ennishi, D; Kondo, Y; Meguro, A; Kin, Y; Minami, Y; Hashimoto, D; Nishiyama, T; Shimada, S; Masaki, Y; Okamoto, M; Atsuta, Y; Kiyoi, H; Suzuki, R; Nakamura, S; Kinoshita, T; Ennishi, D; Kondo, Y; Meguro, A; Kin, Y; Minami, Y; Hashimoto, D; Nishiyama, T; Shimada, S; Masaki, Y; Okamoto, M; Atsuta, Y; Kiyoi, H; Suzuki, R; Nakamura, S; Kinoshita, T

    ECLINICALMEDICINE   Vol. 80   page： 103078   2025.2

    　More details

    Language：English   Publisher：eClinicalMedicine  

    Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and efficacy of standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted a multicentre, single-arm, phase 2 trial in untreated IVLBCL patients without CNS involvement at diagnosis (PRIMEUR-IVL). In the primary analysis, the PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) of 76% and 2-year overall survival (OS) of 92% with a low incidence (3%) of secondary CNS involvement (sCNSi). Methods: We present a prespecified final analysis of the PRIMEUR-IVL study including 5-year PFS, OS and cumulative incidence of sCNSi. Participants were enrolled between June 2011 and July 2016, and the data cutoff date for the final analysis was 16 November 2021. The trial was registered in the UMIN Clinical Trial Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165). Findings: With a median follow-up of 7.1 years (interquartile range 5.6–8.7), 5-year PFS in all 37 eligible patients was 68% (95% confidence interval [CI] 50%–80%) and OS was 78% (95% CI 61%–89%). No additional sCNSi was observed after the primary analysis. Severe adverse events after the primary analysis were grade 4 neutropenia (n = 1) and grade 4 myelodysplastic syndrome that did not require specific treatment (n = 1). Eight deaths occurred during the observation period after enrolment, due to primary disease (n = 6), sepsis (n = 1) and unknown sudden death (n = 1). Interpretation: Long-term follow-up data demonstrated durable response for PFS and OS, and low cumulative incidence of sCNSi, indicating the efficacy of standard chemotherapy combined with CNS-directed therapy for untreated IVLBCL patients. Funding: This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.

    DOI： 10.1016/j.eclinm.2025.103078

    Open Access

    Web of Science

    Scopus

    PubMed

  2. Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma

    Takai, M; Shimada, K; Furukawa, K; Yamaga, Y; Yoshiyama, S; Kagaya, Y; Suzuki, T; Hayashi, K; Shimada, S; Karube, K; Kiyoi, H

    CANCER SCIENCE   Vol. 116 ( 1 ) page： 214 - 225   2025.1

    　More details

    Language：English   Publisher：Cancer Science  

    Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma that is characterized by the proliferation of lymphoma cells in the lumina of small vessels. Recent progress uncovering the genetic characteristics associated with MYD88/CD79B mutations has stimulated interest in the use of drugs targeting B-cell receptor signaling, including Bruton's tyrosine kinase. However, difficulties in culturing ex vivo IVLBCL cells has hampered research on the development of novel therapies. In the present study, we demonstrated the establishment of an ex vivo culture system of IVLBCL cells obtained from patient-derived xenograft (PDX) models. The spheroid culture enabled us to culture IVLBCL PDX cells for more than 10 days and to explore the efficacy of drug treatments acting on these cells. We found that carfilzomib and ibrutinib were effective for treating IVLBCL in ex vivo experiments and conducted in vivo analyses to assess the efficacy of these drugs. Although the efficacy of carfilzomib was difficult to confirm due to its toxicity in our models, ibrutinib showed comparable efficacy to a standard combination of chemotherapy drugs. Together, our data provide a new culture method for IVLBCL PDX cells and a rationale for translating ibrutinib to clinical use in IVLBCL patients.

    DOI： 10.1111/cas.16310

    Web of Science

    Scopus

    PubMed

  3. Predictive Performance of Radiomic Features Extracted from Breast MR Imaging in Postoperative Upgrading of Ductal Carcinoma <i>in Situ</i> to Invasive Carcinoma

    Satake Hiroko, Kinoshita Fumie, Ishigaki Satoko, Kato Keita, Jo Yusuke, Shimada Satoko, Masuda Norikazu, Naganawa Shinji

    Magnetic Resonance in Medical Sciences   Vol. advpub ( 0 )   2024.5

    　More details

    Language：English   Publisher：Japanese Society for Magnetic Resonance in Medicine  

    <p>Purpose: To investigate the predictive performance of radiomic features extracted from breast MRI for upgrade of ductal carcinoma <i>in situ</i> (DCIS) to invasive carcinoma.</p><p>Methods: This retrospective study included 71 women with DCIS lesions diagnosed preoperatively by biopsy. All women underwent breast dynamic contrast-enhanced (DCE) MRI of the breast, which included pre-contrast and five post-contrast phases continuously with a time resolution of 60s. Lesion segmentation was performed manually, and 144 radiomic features of the lesions were extracted from T2-weighted images (T2WI), pre-contrast T1-weighted images (T1WI), and post-contrast 1st, 2nd, and 5th phase subtraction images on DCE-MRI. Qualitative features of mammography, ultrasound, and MRI were also assessed. Clinicopathological features were evaluated using medical records. The least absolute shrinkage and selection operator (LASSO) algorithm was applied for features selection and model building. The predictive performance of postoperative upgrade to invasive carcinoma was assessed using the area under the receiver operating characteristic curve.</p><p>Results: Surgical specimens revealed 13 lesions (18.3%) that were upgraded to invasive carcinoma. Among clinicopathological and qualitative features, age was the only significant predictive variable. No significant radiomic features were observed on T2WI and post-contrast 2nd phase subtraction images on DCE-MRI. The area under the curves (AUCs) of the LASSO radiomics model integrated with age were 0.915 for pre-contrast T1WI, 0.862 for post-contrast 1st phase subtraction images, and 0.833 for post-contrast 5th phase subtraction images. The AUCs of the 200-times bootstrap internal validations were 0.885, 0.832, and 0.775.</p><p>Conclusion: A radiomics approach using breast MRI may be a promising method for predicting the postoperative upgrade of DCIS. The present study showed that the radiomic features extracted from pre-contrast T1WI and post-contrast subtraction images in the very early phase of DCE-MRI were more predictable.</p>

    DOI： 10.2463/mrms.mp.2023-0168

    Web of Science

    PubMed

    CiNii Research

  4. Clinicopathological characteristics associated with the engraftment of patient lymphoma cells in NOG mice

    Sahashi, S; Shimada, K; Takagi, Y; Aoki, T; Kunou, S; Sakamoto, A; Murase, A; Furukawa, K; Kagaya, Y; Yamaga, Y; Takai, M; Tokuyama, K; Shimada, S; Nakamura, S; Kiyoi, H

    INTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 118 ( 2 ) page： 221 - 230   2023.8

    　More details

    Language：English   Publisher：International Journal of Hematology  

    Patient-derived xenograft (PDX) mouse models are useful for deepening our understanding of the biology of malignant lymphoma; however, factors associated with the success of the PDX lymphoma model are largely unknown. We retrospectively analyzed the characteristics of 66 xenotransplantations from 65 patients. In all, 43 (65%) specimens were obtained from patients aged > 60 years, and 42 (64%) specimens were obtained at diagnosis. Specimens were obtained from patients with the following diseases: diffuse large B-cell lymphoma (n = 30), intravascular large B-cell lymphoma (n = 12), follicular lymphoma (n = 8), peripheral T-cell lymphoma (n = 7), mantle cell lymphoma (n = 2), and other (n = 7). The specimens were sourced mainly from bone marrow (n = 31, 47%) and extranodal tumors (n = 13, 20%). Engraftment was successful in 33/66 (50%) xenotransplantations. The median age of patients who provided successful specimens was significantly higher than that for unsuccessful specimens (p = 0.013). Specimens with a high proportion of tumor cells in the graft and those obtained from patients with relapsed/refractory disease showed higher tendencies toward successful engraftment. Taken together, these data suggest that tumor cells with a highly malignant potential might have a high likelihood of engraftment.

    DOI： 10.1007/s12185-023-03604-z

    Web of Science

    Scopus

    PubMed

  5. Two cases of solitary fibrous tumor/hemangiopericytoma with different clinical features according to the World Health Organization classification: case report and review of the literature.

    Nishii T, Nagashima Y, Nishimura Y, Ito H, Oyama T, Matsuo M, Sakakibara A, Shimada S, Saito R

    Journal of spine surgery (Hong Kong)   Vol. 7 ( 4 ) page： 532 - 539   2021.12

    　More details

    Language：English  

    DOI： 10.21037/jss-21-83

    PubMed

  6. Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma

    Kunou Shunsuke, Shimada Kazuyuki, Takai Mika, Sakamoto Akihiko, Aoki Tomohiro, Hikita Tomoya, Kagaya Yusuke, Iwamoto Eisuke, Sanada Masashi, Shimada Satoko, Hayakawa Fumihiko, Oneyama Chitose, Kiyoi Hitoshi

    ONCOGENE   Vol. 40 ( 23 ) page： 3989 - 4003   2021.6

    　More details

    Language：Japanese   Publisher：Oncogene  

    The tumor microenvironment is deeply involved in the process of tumor growth and development. In this study, we focused on cancer-associated fibroblasts (CAFs) and their derived exosomes on the lymphoma microenvironment to uncover their clinical significance. CAFs were established from primary lymphoma samples, and exosomes secreted from CAFs were obtained by standard procedures. We then investigated the roles of CAFs and their derived exosomes in the survival and drug resistance of lymphoma cells. CAFs supported the survival of lymphoma cells through increased glycolysis, and the extent differed among CAFs. Exosomes were identified as a major component of the extracellular vesicles from CAFs, and they also supported the survival of lymphoma cells. The suppression of RAB27B, which is involved in the secretion of exosomes, using a specific siRNA resulted in reduced exosome secretion and decreased survival of lymphoma cells. Moreover, anti-pyrimidine drug resistance was induced in the presence of exosomes through the suppression of the pyrimidine transporter, equilibrative nucleoside transporter 2 (ENT2), and the suppression of ENT2 was significant in in vivo experiments and clinical samples. RNA sequencing analysis of miRNAs in exosomes identified miR-4717-5p as one of the most abundant miRNAs in the exosome, which suppressed the expression of ENT2 and induced anti-pyrimidine drug resistance in vitro. Our results suggest that exosomes including miR-4717-5p secreted from CAFs play a pivotal role in the lymphoma microenvironment, indicating that they are a promising therapeutic target.

    DOI： 10.1038/s41388-021-01829-y

    Web of Science

    Scopus

    PubMed

  7. The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma

    Morichika Kazuho, Karube Kennosuke, Sakihama Shugo, Watanabe Risa, Kawaki Mamoru, Nishi Yukiko, Nakachi Sawako, Okamoto Shiki, Takahara Taishi, Satou Akira, Shimada Satoko, Shimada Kazuyuki, Tsuzuki Toyonori, Fukushima Takuya, Morishima Satoko, Masuzaki Hiroaki

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   Vol. 45 ( 6 ) page： 832 - 840   2021.6

    　More details

    Language：Japanese   Publisher：American Journal of Surgical Pathology  

    On the basis of immunohistochemistry, diffuse large B-cell lymphoma (DLBCL) is categorized as a germinal center B-cell (GCB) or non-GCB subtype. Recent integrated genomic analyses have highlighted the importance of the JAK-STAT3 pathway in the molecular pathogenesis of DLBCL. However, its relevance to clinical outcomes remains controversial. Therefore, we evaluated the extent of the nuclear expression of phosphorylated STAT3 (pSTAT3), a surrogate marker of signal transducer and activator of transcription 3 (STAT3) activation, by immunohistochemistry. We also analyzed the potential relationship between pSTAT3 positivity (defined as ≥ 40% positive neoplastic cells) and clinicopathologic characteristics in 294 patients with DLBCL. pSTAT3 was detected in 122 patients (42%), with a higher rate in the non-GCB subtype than in the GCB subtype (57% vs. 28%, P < 0.001). Factors potentially activating STAT3, MYD88L265P, and Epstein-Barr virus-encoded small RNA were identified in the pSTAT3-positive non-GCB subtype, whereas the pSTAT3-positive GCB subtype often showed STAT3 mutations and lacked EZH2 mutations and the rearrangements of BCL2 and MYC. Multivariate analyses revealed that the pSTAT3-positive GCB subtype showed a favorable prognosis (HR: 0.17; 95% confidence interval, 0.04-0.7; P = 0.014). These findings suggest that pSTAT3 positivity may have a unique impact on the clinicopathologic characteristics of DLBCL, making it a promising novel marker for the favorable prognosis of patients with the GCB subtype.

    DOI： 10.1097/PAS.0000000000001691

    Web of Science

    Scopus

    PubMed

  8. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.

    Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H

    Blood   Vol. 137 ( 11 ) page： 1491 - 1502   2021.3

    　More details

  9. Unusual presentation of recurrent follicular lymphoma as diffuse granular shadow

    Ito Takayasu, Okachi Shotaro, Ishikawa Yuichi, Shimada Satoko, Wakahara Keiko, Hashimoto Naozumi

    RESPIROLOGY CASE REPORTS   Vol. 9 ( 3 ) page： e00710   2021.3

    　More details

    Publisher：Respirology Case Reports  

    DOI： 10.1002/rcr2.710

    Web of Science

    Scopus

    PubMed

  10. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review

    Sakakibara Ayako, Kohno Kei, Ishikawa Eri, Suzuki Yuka, Tsuyuki Yuta, Shimada Satoko, Shimada Kazuyuki, Satou Akira, Takahara Taishi, Ohashi Akiko, Takahashi Emiko, Kato Seiichi, Nakamura Shigeo, Asano Naoko

    Journal of Clinical and Experimental Hematopathology   Vol. 61 ( 4 ) page： 182 - 191   2021

    　More details

    Language：Japanese   Publisher：The Japanese Society for Lymphoreticular Tissue Research  

    <p>The programmed cell death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in tumor cell escape from immune control and has been most extensively investigated for therapeutic purposes. However, PD-L1 immunohistochemistry is still not used widely for diagnosis. We review the diagnostic utility of PD-L1 (by clone SP142) immunohistochemistry in large-cell lymphomas, mainly consisting of classic Hodgkin lymphoma (CHL) and diffuse large B-cell lymphoma (DLBCL). Neoplastic PD-L1 (nPD-L1) expression on Hodgkin and Reed-Sternberg cells is well-established among prototypic CHL. Of note, EBV+ CHL often poses a challenge for differential diagnosis from peripheral T-cell lymphoma with EBV+ non-malignant large B-cells; their distinction is based on the lack of PD-L1 expression on large B-cells in the latter. The nPD-L1 expression further provides a good diagnostic consensus for CHL with primary extranodal disease conceivably characterized by a combined pathogenesis of immune escape of tumor cells and immunodeficiency. Compared with CHL, the nPD-L1 expression rate is much lower in DLBCL, highlighting some specific subgroups of intravascular large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and EBV+ DLBCL. They consist of nPD-L1-positive and -negative subgroups, but their clinicopathological significance remains to be elucidated. Microenvironmental PD-L1 positivity on immune cells may be associated with a favorable prognosis in extranodal DLBCL. PD-L1 (by SP142) immunohistochemistry has helped us to understand the immune biology of lymphoid neoplasms possibly related by immune escape and/or immunodeficiency. However, knowledge of these issues remains limited and should be clarified for diagnostic consensus in the future.</p>

    DOI： 10.3960/jslrt.21003

    Web of Science

    PubMed

    CiNii Research

  11. Lymphocyte-depleted classic Hodgkin lymphoma with primary extranodal disease: Two cases that highlight the combination of immunodeficiency and immune escape in the pathogenesis

    Tsuyuki Yuta, Kohno Kei, Inagaki Yuichiro, Sakai Yu, Kosugi Hiroshi, Takahashi Emiko, Suzuki Yuka, Shimada Satoko, Kato Seiichi, Takahara Taishi, Satou Akira, Shimoyama Yoshie, Nakamura Shigeo, Asano Naoko, Sakakibara Ayako

    Journal of Clinical and Experimental Hematopathology   Vol. 61 ( 3 ) page： 173 - 179   2021

    　More details

    Language：Japanese   Publisher：The Japanese Society for Lymphoreticular Tissue Research  

    <p>Neoplastic programmed cell death ligand 1 (PD-L1) expression, activated by <i>PD-L1</i> gene alterations, is strongly associated with classic Hodgkin lymphoma (CHL). This association enabled a diagnostic consensus for lymphocyte-depleted CHL (LD-CHL), a previously enigmatic disease. We describe two patients with LD-CHL and primary extranodal disease. One patient was a 92-year-old female (Case #1) with a large mass that involved the uterus combined with swollen lymph nodes in the pelvic cavity. The second patient was a 76-year-old female (Case #2) with human T-cell leukemia virus type 1 (HTLV-1) who initially exhibited massive bone marrow involvement without peripheral lymphadenopathies. Biopsies of these tumors from the cervix uteri and bone marrow, respectively, revealed lesions rich in Hodgkin and Reed-Sternberg (H-RS) cells and diminished populations of other cell populations. Immunohistochemistry demonstrated that these H-RS cells expressed CD30, BOB1, and fascin, but not CD15, CD20, PAX5, or OCT2. They also expressed PD-L1, which led to our preferred diagnosis of LD-CHL in both patients. Epstein-Barr virus was associated with LD-CHL in Case #1, but not in Case #2. Both patients were deemed too frail for treatment. They died of disease at 1 (Case #1) and 15 months (Case #2) after the diagnosis. These findings highlight the abnormal biological behavior of this immune-escape-related lymphoid neoplasm in patients with immunodeficiency due to immune senescence and HTLV1 infection.</p>

    DOI： 10.3960/jslrt.21008

    Web of Science

    PubMed

    CiNii Research

  12. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV plus lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142

    Sakakibara Ayako, Kohno Kei, Ishikawa Eri, Suzuki Yuka, Shimada Satoko, Eladl Ahmed E., Elsayed Ahmed A., Daroontum Teerada, Satou Akira, Takahara Taishi, Ohashi Akiko, Takahashi Emiko, Kato Seiichi, Nakamura Shigeo, Asano Naoko

    PATHOLOGY INTERNATIONAL   Vol. 70 ( 8 ) page： 481 - 492   2020.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pin.12946

    Web of Science

    Scopus

    PubMed

  13. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy

    Suzuki Yuka, Kohno Kei, Matsue Kosei, Sakakibara Ayako, Ishikawa Eri, Shimada Satoko, Shimada Kazuyuki, Mabuchi Seiyo, Takahara Taishi, Kato Seiichi, Nakamura Shigeo, Satou Akira

    CANCER MEDICINE   Vol. 9 ( 13 ) page： 4768 - 4776   2020.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/cam4.3104

    Web of Science

    Scopus

    PubMed

  14. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial

    Shimada Kazuyuki, Yamaguchi Motoko, Atsuta Yoshiko, Matsue Kosei, Sato Keijiro, Kusumoto Shigeru, Nagai Hirokazu, Takizawa Jun, Fukuhara Noriko, Nagafuji Koji, Miyazaki Kana, Ohtsuka Eiichi, Okamoto Masataka, Sugita Yasumasa, Uchida Toshiki, Kayukawa Satoshi, Wake Atsushi, Ennishi Daisuke, Kondo Yukio, Izumi Tohru, Kin Yoshihiro, Tsukasaki Kunihiro, Hashimoto Daigo, Yuge Masaaki, Yanagisawa Atsumi, Kuwatsuka Yachiyo, Shimada Satoko, Masaki Yasufumi, Niitsu Nozomi, Kiyoi Hitoshi, Suzuki Ritsuro, Tokunaga Takashi, Nakamura Shigeo, Kinoshita Tomohiro

    LANCET ONCOLOGY   Vol. 21 ( 4 ) page： 593 - 602   2020.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/S1470-2045(20)30059-0

    Web of Science

    Scopus

    PubMed

  15. Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases

    Sakakibara Ayako, Kohno Kei, Iwakoshi Akari, Moritani Suzuko, Fujishiro Aya, Kito Katsuyuki, Suzuki Yuka, Shimada Satoko, Nakaguro Masato, Shimoyama Yoshie, Takahara Taishi, Takahashi Emiko, Ohashi Akiko, Satou Akira, Kato Seiichi, Asano Naoko, Nakamura Shigeo

    PATHOLOGY INTERNATIONAL   Vol. 70 ( 2 ) page： 116 - 122   2020.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pin.12891

    Web of Science

    Scopus

    PubMed

  16. Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry

    Kohno Kei, Sakakibara Ayako, Iwakoshi Akari, Hasegawa Masaki, Adachi Shiro, Ishikawa Eri, Suzuki Yuka, Shimada Satoko, Nakaguro Masato, Shimoyama Yoshie, Takahara Taishi, Takahashi Emiko, Ohashi Akiko, Satou Akira, Kato Seiichi, Asano Naoko, Nakamura Shigeo

    PATHOLOGY INTERNATIONAL   Vol. 70 ( 2 ) page： 108-115   2020.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pin.12888

    Web of Science

    Scopus

    PubMed

  17. Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

    Shimada Kazuyuki, Yamaguchi Motoko, Atsuta Yoshiko, Matsue Kosei, Sato Keijiro, Kusumoto Shigeru, Nagai Hirokazu, Takizawa Jun, Fukuhara Noriko, Nagafuji Koji, Miyazaki Kana, Ohtsuka Eiichi, Okamoto Masataka, Sugita Yasumasa, Uchida Toshiki, Kayukawa Satoshi, Wake Atsushi, Ennishi Daisuke, Kondo Yukio, Izumi Tohru, Kin Yoshihiro, Tsukasaki Kunihiro, Hashimoto Daigo, Yuge Masaaki, Yanagisawa Atsumi, Kuwatsuka Yachiyo, Shimada Satoko, Masaki Yasufumi, Niitsu Nozomi, Kiyoi Hitoshi, Suzuki Ritsuro, Tokunaga Takashi, Nakamura Shigeo, Kinoshita Tomohiro

    BLOOD   Vol. 134   2019.11

    　More details

  18. Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma

    Sakakibara Ayako, Inagaki Yuichiro, Imaoka Eiki, Sakai Yu, Ito Masafumi, Ishikawa Eri, Shimada Satoko, Shimada Kazuyuki, Suzuki Yuka, Nakamura Shigeo, Satou Akira, Kohno Kei

    PATHOLOGY INTERNATIONAL   Vol. 69 ( 3 ) page： 148-154   2019.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pin.12757

    Web of Science

    Scopus

    PubMed

  19. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma

    Suzuki Yuka, Sakakibara Ayako, Shimada Kazuyuki, Shimada Satoko, Ishikawa Eri, Nakamura Shigeo, Kato Seiichi, Takahara Taishi, Asano Naoko, Satou Akira, Kohno Kei

    PATHOLOGY INTERNATIONAL   Vol. 69 ( 1 ) page： 13-20   2019.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pin.12742

    Web of Science

    Scopus

    PubMed

  20. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells

    Sakakibara Ayako, Kohno Kei, Eladl Ahmed E., Klaisuwan Teerada, Ishikawa Eri, Suzuki Yuka, Shimada Satoko, Nakaguro Masato, Shimoyama Yoshie, Takahara Taishi, Kato Seiichi, Asano Naoko, Nakamura Shigeo, Satou Akira

    HISTOPATHOLOGY   Vol. 72 ( 7 ) page： 1156-1163   2018.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/his.13475

    Web of Science

    Scopus

    PubMed

  21. Anaplastic variant of diffuse large B-cell lymphoma with hallmark cell appearance: Two cases highlighting a broad diversity in the diagnostics

    Sakakibara Ayako, Kohno Kei, Kuroda Naoto, Yorita Kenji, Megahed Nirmeen A., Eladl Ahmed E., Daroontum Teerada, Ishikawa Eri, Suzuki Yuka, Shimada Satoko, Nakaguro Masato, Shimoyama Yoshie, Satou Akira, Kato Seiichi, Yatabe Yasushi, Asano Naoko, Nakamura Shigeo

    PATHOLOGY INTERNATIONAL   Vol. 68 ( 4 ) page： 251-255   2018.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/pin.12653

    Web of Science

    Scopus

    PubMed

  22. Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression

    Sakakibara Ayako, Inagaki Yuichiro, Imaoka Eiki, Ishikawa Eri, Shimada Satoko, Shimada Kazuyuki, Suzuki Yuka, Nakamura Shigeo, Satou Akira, Kohno Kei

    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY   Vol. 58 ( 1 ) page： 32-35   2018

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3960/jslrt.17037

    Web of Science

    PubMed

  23. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism

    Aoki Tomohiro, Shimada Kazuyuki, Sakamoto Akihiko, Sugimoto Keiki, Morishita Takanobu, Kojima Yuki, Shimada Satoko, Kato Seiichi, Iriyama Chisako, Kuno Shunsuke, Harada Yasuhiko, Tomita Akihiro, Hayakawa Fumihiko, Kiyoi Hitoshi

    ONCOTARGET   Vol. 8 ( 8 ) page： 13085-13098   2017.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.18632/oncotarget.14393

    Web of Science

    Scopus

    PubMed

  24. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.

    Kato S, Miyata T, Takata K, Shimada S, Ito Y, Tomita A, Elsayed AA, Takahashi E, Asano N, Kinoshita T, Kimura H, Nakamura S.

    Hum Pathol.   Vol. 44 ( 12 ) page： 2849-52.   2013

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  25. An autopsy case of lymphomatosis cerebri showing pathological changes of intravascular large B-cell lymphoma in visceral organs.

    Hishikawa N, Niwa H, Hara T, Hara K, Ito M, Shimada S, Yoshida M, Hashizume Y, Murakami N.

    Neuropathology   Vol. 31 ( 6 ) page： 612-9.   2011

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  26. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.

    Imai H, Shimada K, Shimada S, Abe M, Okamoto M, Kitamura K, Kinoshita T, Shiraishi T, Nakamura S.

    Pathol Int.   Vol. 59 ( 7 ) page： 431-7   2009

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  27. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases.

    Takahashi E, Asano N, Li C, Tanaka T, Shimada K, Shimada S, Yoshino T, Kojima M, Hara K, Eimoto T, Nakamura S

    Histopathology   Vol. 52 ( 5 ) page： 585-96   2008

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  28. 後腹膜軟部腫瘍の１例

    和佐潤志　西田佳弘　筑紫聡　紫藤洋二　下山芳江　島田聡子　長坂徹郎　中村栄男

    東海骨軟部腫瘍   Vol. 20   page： 25-26   2008

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  29. 右側胸部軟部腫瘍の１例

    細野幸三　西田佳弘　筑紫聡　紫藤洋二　島田聡子　下山芳江　長坂徹郎　中村栄男

    東海骨軟部腫瘍   Vol. 20   page： 13-14   2008

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  30. 本邦におけるintravascular large B-cell lymphomaの臨床病理

    島田聡子　中村栄男

    annual review 2008 血液     page： 150-154   2008

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  31. Substained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell lymphoma Reviewed

    K Shimada, H Kosugi, H Narimatsu, S Shimada, T Suzuki, M Ito, T Kinoshita, N Mori, T Naoe

    Journal of Clinical and Experimental Hematopathology   Vol. 48   page： 25-28   2008

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  32. Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography.

    Shimada K, Kosugi H, Shimada S, Narimatsu H, Koyama Y, Suzuki N, Yuge M, Nishibori H, Iwata Y, Nakamura S, Naoe T, Kinoshita T.

    Int J Hematol.   Vol. 88 ( 2 ) page： 149-53.   2008

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  33. *Nestin expression as a new marker in malignant peripheral nerve sheath tumors Reviewed

    Satoko Shimada, Toyonori Tsuzuki, Makoto Kuroda, Tetsuro Nagasaka, Kazuo Hara, Emiko Takahashi, Seijun Hayakawa, Kenzo Ono, Nagako Maeda, Naoyoshi Mori, Peter B. Illei

    Pathology International   Vol. 57   page： 60-67   2007

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  34. Intracranial lesion of Erdheim-Chester disease Reviewed

    Satoko Shimada, Kenzo Ono, Yoshio Hashizume, Masato Nakaguro, Yasuhiko Suzuki, Naoyoshi Mori

    Human Pathology   Vol. 38   page： 950-954   2007

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  35. Fatal varicella infection in a girl with systemic lupus erythematosus after oral scyclovir prophylaxis. Reviewed

    I Hirose, H Yahaguchi, D Inaguma, K Ono, S Shimada, J Kawada, K Shiraki, H Kimura

    Eur J Pediatr   Vol. 165   page： 280-281   2006

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  36. TIA-1 expresion in hairy cell leukemia Reviewed

    Naoyoshi Mori, Yoshiko Idate Murakami, Satoko Shimada, Sachiko Iwamizu-Watanabe, Yoriko Yamashita, Yuichi Hasegawa, Hiroshi Kojima, Toshiro Nagasawa

    Modern Pathology   Vol. 17   page： 840-846   2004

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  37. 腹腔内出血で発症したSegmental Arterial Mediolysis (SAM)の一例

    島田聡子、池田耕介、森尚義

    現代医学   Vol. 51   page： 503-507   2004

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

  38. Malignant mesothelioma of the tunica vaginalis testis: a case with a predominant sarcomatous component. Reviewed

    Satoko Shimada, Kenzo Ono, Yasuhiko Suzuki, Naoyoshi Mori

    Pathology International   Vol. 54   page： 930-934   2004

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  39. Neuronal Nitric Oxide Synthase-Membrane Phospholipid Interactions Reviewed

    Yasuo Watanabe, Masahiro Nishio, Satoko Hamaji, Yuji Hayashi, Yu Hu, Hiroyoshi Hidaka

    Archives of Biochemistry and Biophysics   Vol. 358 ( 1 ) page： 68-73   1998

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  40. Inter-isoformal regulation of nitric oxide synthase through heteromeric dimerization Reviewed

    Yasuo Watanabe, Masahiro Nishio, Satoko Hamaji, Hiroyoshi Hidaka

    Biochimica et Biophysica Acta   Vol. 1388   page： 199-208   1998

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

▼display all

To the head of Papers.▲

MISC 5

  1. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma

    Kazuyuki Shimada 1 2 , Kenichi Yoshida 3 , Yasuhiro Suzuki 1 4 , Chisako Iriyama 1 5 , Yoshikage Inoue 3 6 , Masashi Sanada 7 , Keisuke Kataoka 3 8 , Masaaki Yuge 9 , Yusuke Takagi 10 11 , Shigeru Kusumoto 12 , Yasufumi Masaki 13 , Takahiko Ito 14 , Yuichiro Inagaki 15 , Akinao Okamoto 5 , Yachiyo Kuwatsuka 16 , Masahiro Nakatochi 17 , Satoko Shimada 18 , Hiroaki Miyoshi 19 , Yuichi Shiraishi 20 , Kenichi Chiba 20 , Hiroko Tanaka 21 , Satoru Miyano 21 22 , Yusuke Shiozawa 23 , Yasuhito Nannya 3 , Asako Okabe 24 , Kei Kohno 18 19 , Yoshiko Atsuta 25 , Koichi Ohshima 19 , Shigeo Nakamura 18 , Seishi Ogawa 3 26 27 , Akihiro Tomita 1 5 , Hitoshi Kiyoi 1

    blood     2021.3

  2. Unusual presentation of recurrent follicular lymphoma as diffuse granular shadow

    Takayasu Ito 1 , Shotaro Okachi 1 , Yuichi Ishikawa 2 , Satoko Shimada 3 , Keiko Wakahara 1 , Naozumi Hashimoto 1

    Respirol Case Rep     2021.3

  3. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142

    Ayako Sakakibara 1 , Kei Kohno 1 , Eri Ishikawa 1 , Yuka Suzuki 1 , Satoko Shimada 1 , Ahmed E Eladl 2 , Ahmed A Elsayed 2 , Teerada Daroontum 3 , Akira Satou 4 , Taishi Takahara 4 , Akiko Ohashi 4 , Emiko Takahashi 4 , Seiichi Kato 5 , Shigeo Nakamura 1 , Naoko Asano 6

    Pathol Int .     2020.8

  4. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy

    Yuka Suzuki 1 , Kei Kohno 1 , Kosei Matsue 2 , Ayako Sakakibara 1 , Eri Ishikawa 1 3 , Satoko Shimada 1 , Kazuyuki Shimada 4 , Seiyo Mabuchi 1 , Taishi Takahara 5 , Seiichi Kato 6 , Shigeo Nakamura 1 , Akira Satou 5

    Cancer Med .     2020.7

  5. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial

    Kazuyuki Shimada 1 , Motoko Yamaguchi 2 , Yoshiko Atsuta 3 , Kosei Matsue 4 , Keijiro Sato 5 , Shigeru Kusumoto 6 , Hirokazu Nagai 7 , Jun Takizawa 8 , Noriko Fukuhara 9 , Koji Nagafuji 10 , Kana Miyazaki 2 , Eiichi Ohtsuka 11 , Masataka Okamoto 12 , Yasumasa Sugita 13 , Toshiki Uchida 14 , Satoshi Kayukawa 15 , Atsushi Wake 16 , Daisuke Ennishi 17 , Yukio Kondo 18 , Tohru Izumi 19 , Yoshihiro Kin 20 , Kunihiro Tsukasaki 21 , Daigo Hashimoto 22 , Masaaki Yuge 23 , Atsumi Yanagisawa 3 , Yachiyo Kuwatsuka 24 , Satoko Shimada 25 , Yasufumi Masaki 26 , Nozomi Niitsu 27 , Hitoshi Kiyoi 28 , Ritsuro Suzuki 29 , Takashi Tokunaga 7 , Shigeo Nakamura 25 , Tomohiro Kinoshita 30

    Lancet Oncol .     2020.4

To the head of MISC.▲

Presentations 3

  1. Wilms' tumor gene (WT1) exxpression in neurogenic and myogenic satcomas International conference

    26th International Congress of the International Academy of Pathology (IAP) 

    　More details

    Event date： 2006.9

    Language：English   Presentation type：Poster presentation  

  2. Nestin Expression in Malignant Peripheral Nerve Sheath Tumor (MPNST) and Other Soft Tissue Tumors International conference

    USCAP, 94th Annual meeting 

    　More details

    Event date： 2005.2

    Language：English   Presentation type：Poster presentation  

  3. TIA-1 Expression in Hairy Cell Leukemia International conference

    United States and Canadian Academy of Pathology (USCAP), 93rd Annual Meeting 

    　More details

    Event date： 2004.3

    Language：English   Presentation type：Poster presentation  

To the head of Presentations.▲

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 非造影MRIによる組織学的構築に基づいた背景乳腺の新分類と高解像度撮像法の開発

    Grant number：24K10883  2024.4 - 2027.3

    科学研究費助成事業  基盤研究(C)

    佐竹 弘子, 石垣 聡子, 島田 聡子, 伊藤 倫太郎

    　 More details

    Authorship：Coinvestigator(s) 

    本研究の目的は、乳房MRIの非造影シークエンスであるT2強調像の高解像度撮像法を新たに開発し、これを用いて背景乳腺の組織学的構築を視覚化および定量化し、乳がんの発症や生物学的特性との関連を検証することである。高解像度撮像法は、拡散強調像にも適用し、機能的情報を融合させることで、乳房MRIの診断能の向上を目指す。本研究により、高解像度非造影MRIによって、乳腺組織の微細構造や微小環境をイメージングできれば、造影剤を用いない非造影乳房検査の実用可能性を高めることができる。また、乳がんのリスク評価に新たな情報をもたらし、乳がん診断および治療の向上に貢献することが見込まれる。

To the head of KAKENHI (Grants-in-Aid for Scientific Research).▲